Efficacy and safety of PARP inhibitors for maintenance treatment of ovarian cancer, regardless of BRCA or HRD status: a comprehensive updated meta-analysis

Abstract

Without taking into account existing biomarkers like genetic mutations (BRCA mutation, Homologous recombination deficiency) with advanced ovarian cancer (OC), the overall survival (OS), progress-free survival (PFS) of the aggregate all groups that have been classified were hazard ratio (HR): 0.72, 95% confidence intervals (CI): 0.66–0.79 and HR: 0.48, 95%CI: 0.44–0.52, respectively. Meanwhile, the OS and PFS of the whole population (regardless of existing genetic mutation markers) were HR: 0.74, 95%CI: 0.64–0.87 and HR: 0.52, 95%CI: 0.42–0.65, separately. Furthermore, the OS and PFS of positive gene mutation markers were HR: 0.71, 95%CI: 0.61–0.83 (HRD and BRACm) and HR: 0.47, 95%CI: 0.42–0.52 (HRD and BRACm), individually. The poly ADP-ribose polymers (PARP) inhibitors have desired efficiency and security in the maintenance treatment of advanced OC patients with BRCAm or BRCAwt, HRD or HRP and unknown gene status.

Keywords:

• Ovarian cancer
• PARP inhibitor
• BRCA
• HRD
• OS
• PFS

Acknowledgment

The author thanks the participants for their cooperation, at the same time, the author is particularly grateful to the Obstetrics and Gynecology Department of Shandong University Qilu Hospital for providing support.

Ethical approval

This study did not involve human or animal experiments, so ethical approval was not required.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.